US Patent Issued to Boehringer Ingelheim International on Aug. 5 for "Glucagon analogues as long-acting GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis" (German Inventor)

ALEXANDRIA, Va., Aug. 6 -- United States Patent no. 12,378,296, issued on Aug. 5, was assigned to Boehringer Ingelheim International GmbH (Ingelheim am Rhein, Germany).

"Glucagon analogues as long-acting GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis" was invented by Leo Thomas (Biberach an der Riss, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to the medical use of specific long-acting glucagon analogues having dual GLP-1/glucagon receptor agonist activity in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic st...